ISDA

Deposition Date 2019-08-25

Release Date 2020-03-04

Last Version Date 2023-10-11

Entry Detail

PDB ID:

6U4J

Keywords:

Oxidoreductase/Inhibitor

Title:

Crystal structure of IDH1 R132H mutant in complex with FT-2102

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.11 Å

R-Value Free:

0.22

R-Value Work:

0.16

R-Value Observed:

0.17

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Isocitrate dehydrogenase [NADP] cytoplasmic
Gene (Uniprot):IDH1
Mutations:R132H
Chain IDs:A, B
Chain Length:425
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O75874 Pfam ID:PF00180 EC:1.1.1.42

Ligand Molecules

FLC

NAP

PWV

Primary Citation

Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.

Caravella, J.A, Lin, J, Diebold, R.B, Campbell, A.M, Ericsson, A, Gustafson, G, Wang, Z, Castro, J, Clarke, A, Gotur, D, Josephine, H.R, Katz, M, Kershaw, M, Yao, L, Toms, A.V, Barr, K.J, Dinsmore, C.J, Walker, D, Ashwell, S, Lu, W.Show

J.Med.Chem. 63 1612 1623 (2020)

PMID: 31971798 DOI: 10.1021/acs.jmedchem.9b01423

Abstact

Inhibition of mutant IDH1 is being evaluated clinically as a treatment option for oncology. Here we describe the structure-based design and optimization of quinoline lead compounds to identify FT-2102, a potent, orally bioavailable, brain penetrant, and selective mIDH1 inhibitor. FT-2102 has excellent ADME/PK properties and reduces 2-hydroxyglutarate levels in an mIDH1 xenograft tumor model. This compound has been selected as a candidate for clinical development in hematologic malignancies, solid tumors, and gliomas with mIDH1.

Legend

Protein

Chemical

Disease

Primary Citation of related structures